Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics (NASDAQ: IMTX) reported Phase 1a dose‑escalation data for its next‑generation TCR Bispecifics, IMA402 (PRAME) and IMA401 (MAGEA4/8), and announced Phase 1b plans on November 12, 2025. IMA402 at the RP2D range (10–30 mg) produced a 30% cORR (6/20) across indications, including 29% in melanoma (4/14), with deep durable responses (two complete metabolic responses ongoing 8 and 18 months). Median PFS was 4.8 months (mFU 6.8); 1‑year OS rate was 94%. IMA401 at ≥1 mg showed activity: 25% cORR in head and neck and 29% in melanoma, with a longest response >2 years. Both candidates showed favorable tolerability; provisional RP2D ranges were identified (IMA402: 10–30 mg; IMA401: 1–2 mg).
Immatics (NASDAQ: IMTX) appointed Amie Krause as Chief People Officer effective October 27, 2025.
Ms. Krause brings more than 20 years of global biopharma HR experience, including prior roles at Dompé, Revance Therapeutics, Atara Biotherapeutics and Amgen. The newly established CPO role will lead human resources, organizational development and operations as Immatics transitions to a commercial-stage company and prepares for potential commercialization of its lead PRAME cell therapy candidate, anzu-cel.
Immatics (NASDAQ: IMTX) reported updated Phase 1b data for one-time anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 metastatic uveal melanoma patients presented at ESMO 2025 on October 20, 2025.
Key outcomes: cORR 67% (10/15), mDOR 11.0 months, mPFS 8.5 months (median follow-up 10.4 months) and mOS not reached at 14.3 months mFU; median liver target lesion shrinkage -49.6%. Safety showed mostly Grade 1–2 CRS; Grade 3 CRS 18.8% and no anzu-cel–related Grade 5 events. A Phase 2 cohort (~30 patients) in metastatic uveal melanoma has been initiated.
Immatics (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on PRAME targeting, has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately. Dr. Ramanan brings over 25 years of experience from prominent companies including Seagen, Gilead Sciences, and Amgen.
The new CFO joins from Anthos Therapeutics, where he previously served as CFO, and succeeds Arnd Christ. Dr. Ramanan's appointment comes at a crucial time as Immatics prepares for the commercial launch of anzu-cel, their PRAME cell therapy for metastatic melanoma patients. His extensive experience includes facilitating product launches, establishing global operations, and enabling corporate transactions.
Immatics (NASDAQ: IMTX) reported Q2 2025 financial results and provided updates on its PRAME-targeting therapies. The company's lead candidate, anzu-cel, demonstrated strong results in Phase 1b melanoma trials with a 56% confirmed objective response rate and 12.1 months median duration of response. The global Phase 3 SUPRAME trial is progressing with interim and final analyses expected in 2026.
Financial highlights include cash position of $560.5 million providing runway into 2H 2027, though Q2 showed increased net loss of $82.4 million versus $21.1 million year-over-year. R&D expenses rose to $52.9 million, reflecting advancement of clinical programs.
The company announced CFO Arnd Christ's planned departure and is searching for a replacement. Multiple clinical updates across its pipeline are expected in Q4 2025, including data from IMA203CD8, IMA402, and IMA401 programs.
Immatics (NASDAQ: IMTX) has announced upcoming presentations of its IMA203 TCR T-cell therapy at the 2025 ASCO Annual Meeting in Chicago. The presentations will feature:
1. An oral presentation with updated data from the Phase 1b trial of IMA203 in metastatic melanoma patients, including extended follow-up data since October 2024 and additional uveal melanoma patient data.
2. A trial-in-progress poster presentation on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior checkpoint inhibitor treatment.
The full abstracts will be available on the ASCO website on May 22, 2025, at 5:00 pm ET. The presentations are scheduled for May 31 and June 2, 2025, during the Developmental Therapeutics - Immunotherapy sessions.
Immatics (NASDAQ: IMTX) reported its full year 2024 financial results and business updates. The company's lead TCR-T cell therapy, IMA203, targeting PRAME in advanced melanoma, has entered Phase 3 trial (SUPRAME) with first patient randomized. Key highlights include:
Phase 1b IMA203 data showed 54% confirmed response rate, 12.1 months median duration of response, and 6 months median progression-free survival in advanced melanoma patients. The company's cash position stands at $628.0 million, extending runway into second half of 2027.
Notable developments include:
- SUPRAME Phase 3 trial enrollment continuing as planned, targeting 360 patients
- Manufacturing facility ready for commercial production with >95% success rate
- IMA203CD8 (second-generation therapy) showing 41% confirmed response rate
- TCER® IMA402 and IMA401 programs advancing with promising initial clinical data
Immatics reported Q3 2024 financial results and clinical updates for its cancer immunotherapy pipeline. Key highlights include first clinical data from TCER® IMA402 showing favorable tolerability and initial responses in melanoma patients. The company plans to start SUPRAME, a Phase 3 trial for ACTengine® IMA203 in melanoma patients, in December 2024. Financial position remains strong with $549.2 million in cash and equivalents as of September 30, 2024, plus an additional $150 million from October's public offering, extending cash runway into 2H 2027. Q3 revenue was $56.7 million, with a net loss of $9.6 million.